Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT03281044
Other study ID # 2017-01050
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date October 24, 2018
Est. completion date March 16, 2020

Study information

Verified date April 2020
Source Psychiatric Hospital of the University of Basel
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The prevalence of psychiatric disorders such as major depression disorder (MDD) is increasing rapidly. Despite advancements in the development of therapeutics, current treatment options have not reached optimal efficacy.

Recent interest has been drawn towards the importance of the biochemical signalling between the gastrointestinal tract and the central nervous system also known as the "microbiome-gut-brain axis". The pathogenesis of gut microbiota in extra intestinal diseases was inspired by massive studies in germ free (GF) animals, which indicated that the gut microbiota plays a role in the normal regulation of behaviour that are relevant to mood, anxiety and stress. However, the exact mechanisms by which intestinal dysbiosis are involved in the development of psychiatric diseases are not completely clarified.

A new method to alter the composition of the gastrointestinal microbiota involves fecal microbiota transplantation (FMT). The goal of FMT is to introduce or restore a stable microbial community in the gut by transplanting intestinal microbiota from a healthy donor to the patient. FMT, as a microbiota-target therapy, is arguably very effective for curing recurrent Clostridium difficile infection and has good outcomes in other intestinal diseases. At the same time, applications in previously unexpected areas, including metabolic diseases, neuropsychiatric disorders, autoimmune diseases, allergic disorders, and tumors have shown health enhancing results. FMT has initially been conducted using colonoscopy. However, recent evidence has shown that treatment with frozen FMT capsules (to be taken orally) is also safe and beneficial in restoring the gut microbiota in patients with various diseases As FMT capsules may be an effective, pragmatical adjuvant therapy (in addition to standard treatment) for depression, this project is aimed at (1) investigating for the first time if single administration of FMT capsules ameliorates depressive symptoms in patients with moderate to severe MDD 4 weeks after treatment and (2) establishing the safety profile of encapsulated FMT in MDD. Furthermore, we will also test if (3) FMT capsules modulates immune signalling and inflammatory processes, (4) Hypothalamic-pituitary-adrenal (HPA) axis responses, (5) neurogenesis, (6) energy balance hormones, (7) gut microbiota composition and (8) brain perfusion, structure and activation.


Recruitment information / eligibility

Status Terminated
Enrollment 4
Est. completion date March 16, 2020
Est. primary completion date March 16, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

- Age = 18, body mass index 20-30 kg/m²

- Able to provide signed and dated informed consent

- Patients with moderate to severe depression (as expressed by a Hamilton Depression Rating Scale (HAMD-17) > 17)

- Treatment as usual for depression

- In- and outpatients at the UPK Basel

Exclusion Criteria:

- Patients with mild MDD (HAMD-17 < 17)

- Comorbid psychiatric disturbances such as substance abuse disorder, bipolar disorder, schizophrenia, eating disorders.

- Current medical conditions such as acute infectious disease,

- Dietary restrictions (vegetarian, vegan, gluten-free, PEG/TPN feeding, and any kind of deviation from the UPK standard catering)

- Recent use of medications besides their anti-depressant medication (within 3 months, mainly antibiotics or probiotic consumption within last six weeks).

- Pregnancy (tested before both MRI scans using the AlereTM TestPack +Plus hCG Urine Test), breast-feeding

- Body Mass Index (BMI) > 30

- Current or recent use of antibiotics (within 3 months before inclusion)

- Anticipated antibiotic use in upcoming 4 weeks

- Inability to read and understand the participant's information and informed consent form

- Inability (e.g. dysphagia) to or unwilling to swallow capsules

- Active vomiting

- Known or suspected toxic megacolon and/or known small bowel ileus

- Major gastrointestinal surgery (e.g. significant bowel resection) within 3 months before enrolment. This does not include appendectomy or cholecystectomy.

- History of total colectomy or bariatric surgery.

- Concurrent intensive induction chemotherapy, radiation therapy or biological treatment for active malignancy. Patients on maintenance chemotherapy may be enrolled only after consultation with a medical monitor.

- Life expectancy < 6 months

- Patients with a history of severe anaphylactic or anaphylactoid food allergy

- Solid organ transplant recipients = 90 days post-transplant or on active treatment for rejection

- Neuropenia (=500 neutrophils/mL) or other severe immunosuppression. Anti-TNF will be permitted. Patients on monoclonal antibodies to B and T cells, glucocorticoids, antimetabolites (azathioprine, 6-mercaptopurine, methotrexate), calcineurin inhbitors (tacrolimus, cyclosporine) and mycophenolate mofetil may be enrolled only after consultation with the medical monitor.

- A condition that would jeopardize the safety or rights of the subject, would make it unlikely for the subject to complete the study, or would confound the results of the study.

Study Design


Intervention

Drug:
Fecal microbiota capsules
Patients will receive FMT capsules DE containing the fecal microbiota drug substance within a gelatin capsule shell. The drug substance is fecal microbiota from a single donor.
Placebo oral capsule
The control condition is a placebo FMT capsule. The FMT placebo capsule is identical in appearance to active capsules, but does not contain human feces, the active pharmaceutical ingredient. Placebo capsules will contain an autoclaved solution of glycerol and saline, contained in an identical gelatin capsule as the active product, including the same enteric polymer coating

Locations

Country Name City State
Switzerland University Psychiatric Clinics (UPK) Basel

Sponsors (1)

Lead Sponsor Collaborator
Psychiatric Hospital of the University of Basel

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Depressive symptoms as measured with the Hamilton Rating Scale for Depression Efficacy measure Change from baseline score to follow-up measurements at 1, 2 and 8 months
Secondary Gut microbiota composition as assessed by 16-S-rRNA sequencing of stool samples Efficacy measure Change from baseline score to follow-up measurement after 1 month
Secondary Cerebral blood flow (measured with arterial spin labeling, mL/100 g/min^10) Efficacy measure Change from baseline score to follow-up measurement after 1 month
Secondary Brain structure (measured with structural magnetic resonance imaging to assess gray matter volume in mm^3, and diffusion tensor imaging to assess fractional anisotropy (dimensionless) and mean diffusivity (m2/s)) Efficacy measure Change from baseline score to follow-up measurement after 1 month
Secondary Brain function (measured Blood-oxygen-level dependent contrast imaging) Efficacy measure Change from baseline score to follow-up measurement after 1 month
Secondary HPA axis function (measured with salivary cortisol awakening responses). Efficacy measure Change from baseline score to follow-up measurement after 1 month
Secondary Neurogenesis (measured with blood levels of BDNF). Efficacy measure Change from baseline score to follow-up measurement after 1 month
Secondary Appetite-regulating hormones (measured with blood levels of ghrelin and leptin). Efficacy measure Change from baseline score to follow-up measurement after 1 month
Secondary Immunoregulation and inflammation (measured with blood levels of macrophage migration inhibitory factor and interleukin 1 beta). Efficacy measure Change from baseline score to follow-up measurement after 1 month
Secondary Cognition (measured with the Trail Making Test) Efficacy measure Change from baseline score to follow-up measurement after 1 month
Secondary Physical activity (measured with a portable wristwatch). Efficacy measure Change from baseline score to follow-up measurement after 1 month
Secondary Sleep quality (measured with 28-channel electroencephalography) Efficacy measure Change from baseline score to follow-up measurement after 1 month
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Completed NCT03142919 - Lipopolysaccharide (LPS) Challenge in Depression Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A